

The information in the press release is intended for investors.

Isofol announces that a Late Breaking Abstract has been accepted by ENA 2024

GOTHENBURG, SWEDEN, October 9, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that a Late Breaking Abstract has been accepted for a poster presentation at ENA 2024, which will take place in Barcelona, Spain, during October 23-25th 2024.

The ENA 2024 EORTC-NCI-AACR's 36th Symposium on Molecular Targets and Cancer Therapeutics is a conference for drug development and translational research. The conference is arranged by EORTC, the (European Organisation for Research and Treatment of Cancer), NCI (National Cancer Institute, USA) and AACR (American Association for Cancer Research).

Posters qualified for Late Breaking Abstracts at ENA are, according to the congress guidelines, those that describe the latest advances that will change daily clinical practice.

The abstract was produced in cooperation with Oncosyne AS and Akershus University Hospital in Oslo, Norway, and is based on the preclinical studies that were conducted earlier this year, whose conclusions support the company's clinical development plan.

Presenter: Dr. Jarle Bruun, PhD, Chief Executive Officer, Oncosyne AS.

Title: "Dose-dependent cytotoxicity of arfolitixorin, a direct-acting folate, versus leucovorin with 5-fluorouracil in patient-derived colorectal cancer tumoroids (PDTs)".

Abstract no: 510-LB, **Poster no:** PB-510

The abstract is published online, <https://event.eortc.org/ena2024>, at 10.00 a.m. on October 23 and the poster will be shown in the conference's Exhibition Hall from 12.00 on the same day.

For more information, please contact

Isofol Medical AB (publ)

Roger Tell, Chief Medical Officer

E-mail: roger.tell@isofolmedical.com

Phone: +46 (0)760 29 39 11

The information was submitted for publication, through the agency of the contact person set out above, at 10:00 CEST on October 9, 2024.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company's drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin's efficacy. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com